Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
3636(c) 3689(c) 3680(c) 3692(c) 3698(c) Last
2 047 200 1 756 900 2 126 900 1 501 800 2 598 500 Volume
-2.60% +1.46% -0.24% +0.33% +0.16% Change
More quotes
Estimated financial data (e)
Sales 2021 975 B 8 562 M 8 562 M
Net income 2021 292 B 2 564 M 2 564 M
Net cash position 2021 461 B 4 049 M 4 049 M
P/E ratio 2021 20,8x
Yield 2021 1,86%
Sales 2022 1 016 B 8 921 M 8 921 M
Net income 2022 296 B 2 603 M 2 603 M
Net cash position 2022 590 B 5 184 M 5 184 M
P/E ratio 2022 20,5x
Yield 2022 2,05%
Capitalization 6 080 B 53 374 M 53 387 M
EV / Sales 2021 5,76x
EV / Sales 2022 5,40x
Nbr of Employees 7 555
Free-Float -
More Financials
Company
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the... 
Sector
Pharmaceuticals
Calendar
02/03 | 03:00amEarnings Release
More about the company
Ratings of Chugai Pharmaceutical Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD
01/24Chugai's Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia in Japan
AQ
01/21CHUGAI PHARMACEUTICAL : Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia..
PU
2021CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2021CHUGAI PHARMACEUTICAL : Signs Joint Research Agreement with NCC for Asian International Co..
PU
2021Launch of Chugai's New TV Commercial 'Protect the Ordinary Days People Cherish' Featuri..
AQ
2021CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indi..
PU
2021CHUGAI PHARMACEUTICAL : Launch of Chugai's New TV Commercial “Protect the Ordinary D..
PU
2021Chugai Pharmaceutical Co., Ltd. - Notice of Board of Director's Resolution on Applicati..
AQ
2021Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenh..
AQ
2021Chugai Pharmaceutical Co. - Update on the Development of Oral COVID-19 Drug Candidate A..
AQ
2021Nikkei 225 Declines 1.8% on Central Bank Outlooks
MT
2021CHUGAI PHARMACEUTICAL : Obtained Highest A-Rating by CDP in Two Categories and SBT Validat..
PU
2021CHUGAI PHARMACEUTICAL : Notice of Board of Director's Resolution on Application for New Ma..
PU
2021CHUGAI PHARMACEUTICAL : In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001) f..
PU
2021CHUGAI PHARMACEUTICAL : Update on the Development of Oral COVID-19 Drug Candidate AT-527 i..
PU
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD
2021Le Nikkei 225 recule de 1,8 % en raison des perspectives des banques centrales
2021Le Nikkei 225 gagne 1,4 % en raison de l'apaisement des inquiétudes concernant l'Omicro..
2021MÄRKTE ASIEN/Fester - Hongkong von schwachen Immobilienaktien gebremst
2021Toshiba compte se scinder en trois entreprises d'ici deux ans
2021Sous pression, Toshiba prévoit de se scinder en trois entreprises
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 698,00 JPY
Average target price 4 862,31 JPY
Spread / Average Target 31,5%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-1.15%53 303
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963